Allogene Therapeutics (ALLO) Net Margin (2021 - 2024)
Historic Net Margin for Allogene Therapeutics (ALLO) over the last 4 years, with Q1 2024 value amounting to 291231.82%.
- Allogene Therapeutics' Net Margin rose 322115200.0% to 291231.82% in Q1 2024 from the same period last year, while for Dec 2024 it was 1151031.82%, marking a year-over-year decrease of 8253160300.0%. This contributed to the annual value of 1170863.64% for FY2024, which is 8263741600.0% down from last year.
- Per Allogene Therapeutics' latest filing, its Net Margin stood at 291231.82% for Q1 2024, which was up 322115200.0% from 375447.62% recorded in Q4 2023.
- In the past 5 years, Allogene Therapeutics' Net Margin registered a high of 2.5% during Q4 2021, and its lowest value of 375447.62% during Q4 2023.
- Its 4-year average for Net Margin is 223087.67%, with a median of 258140.91% in 2023.
- Per our database at Business Quant, Allogene Therapeutics' Net Margin tumbled by 2000000000bps in 2022 and then surged by 437442800bps in 2023.
- Quarter analysis of 4 years shows Allogene Therapeutics' Net Margin stood at 2.5% in 2021, then crashed by -14392819bps to 360146.15% in 2022, then decreased by -4bps to 375447.62% in 2023, then increased by 22bps to 291231.82% in 2024.
- Its last three reported values are 291231.82% in Q1 2024, 375447.62% for Q4 2023, and 258140.91% during Q3 2023.